ADHD Medication Shortages Lead to DEA Increasing Drug Allotment
Friday, 6 September 2024, 12:21
ADHD Medication Shortages and the DEA's Response
In response to the ongoing Adderall shortages, the DEA has announced a substantial increase in the allowed production of lisdexamfetamine, commonly known as Vyvanse. The new quota will raise the current limit of 26,500 kg by approximately 6,236 kg, bringing the total to 32,736 kg. This adjustment aims to alleviate the impact on patients relying on these controlled substances.
Details of the DEA’s Quota Increase
- Increased production: The DEA highlights a need for more production to combat ongoing shortages.
- Specific percentage: The increase stands at 23.5%, a significant adjustment reflecting the demand for ADHD medications.
- Impact on patients: Improved access to essential medications like Adderall and Vyvanse for those diagnosed with ADHD.
FDA's Role in Addressing Shortages
In conjunction with the DEA, the FDA is actively involved in monitoring and addressing these shortages to ensure patient care is not compromised.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.